GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate (ADC) as a threat to Amgen and Merck & Co. in the lung cancer field.
The phase 3 trial, sponsored by GSK’s partner Hansoh Pharma, enrolled 461 small cell lung cancer (SCLC) patients at sites in China. Participants, all of whom had relapsed after first-line platinum-based therapy, received the B7-H3-directed ADC ris-rez or the chemotherapy medicine topotecan intravenously every three weeks.
Median OS was 18.5 months in the ris-rez cohort, compared to 10.3 months in the topotecan arm. The result was statistically significant, achieving the trial’s primary endpoint, and compares favorably to data on other second-line treatments for SCLC.
Amgen linked its DLL3xCD3 T-cell engager Imdelltra to a median OS of 13.6 months in a phase 3 trial, versus 8.3 months in people who received one of three chemotherapy drugs, including topotecan. Meanwhile, Merck and Daiichi Sankyo are seeking FDA approval for a B7-H3-directed ADC, ifinatamab deruxtecan (I-DXd), based on a phase 2 trial that reported a median OS of 12.0 months in second-line SCLC.
Differences between the studies confound efforts to compare the data. One obvious variation is that the ris-rez trial only worked with sites in China, while the studies of Imdelltra and I-DXd were global. As Western drugmakers have increasingly turned to China for new cancer drugs, uncertainty about whether clinical data generated in the country will translate to global studies has become a key question.
Hesham Abdullah, M.D., global head of oncology, research and development at GSK, addressed the topic on a media call. The consistency of Chinese and global data on mocertatug rezetecan, the B7-H4-directed ADC that GSK is developing with Hansoh, increases confidence that the ris-rez results can translate globally, Abdullah said. Chinese and global patients take similar drugs before trying ris-rez, he added.
Given evidence of similar treatment pathways and outcomes, Abdullah framed parallel development of ris-rez in Hansoh’s Chinese trials and GSK’s global studies as an advantage. GSK has near-real-time access to Hansoh’s results, giving it “two independent data sets that are being replicated” to inform decisions about which indications to prioritize, the executive said.
GSK started a global phase 3 ris-rez trial in relapsed SCLC last year and expects to publish pivotal data in 2027. While this timeline puts GSK behind its rivals, Abdullah suggested safety could be a potential differentiator for ris-rez. He noted that interstitial lung disease (ILD) is associated with some other platforms. Daiichi and Merck reported two fatal treatment-related ILD/pneumonitis events in their midphase I-DXd trial.
Hansoh reported no grade 4 or 5 ILD events in its phase 3 trial. Ris-rez is associated with the adverse event, with Hansoh reporting a similar proportion of grade 3 ILD events—3.9%—as Daiichi and Merck saw in their I-DXd study. Even so, the absence of fatal events in the Hansoh trial points to a possible edge for the GSK-partnered ADC.
Evidence that ris-rez is differentiated could increase investor interest in an asset that has attracted little fanfare to date. The differentiation of ris-rez is “unclear to us at the moment,” Guggenheim Securities analysts said in a July note to investors, adding that they ascribed limited risk-adjusted sales to the asset and the rest of GSK’s ADC portfolio.
Facts Only
* GSK and Hansoh Pharma are developing risvutatug rezetecan (ris-rez).
* Ris-rez is a B7-H3-directed antibody-drug conjugate.
* A phase 3 trial for relapsed small cell lung cancer (SCLC) took place at sites in China.
* The trial enrolled 461 patients who relapsed after first-line platinum-based therapy.
* Ris-rez achieved a median overall survival (OS) of 18.5 months.
* Topotecan achieved a median OS of 10.3 months.
* Amgen's Imdelltra reported a median OS of 13.6 months in a phase 3 trial.
* Merck and Daiichi Sankyo's ifinatamab deruxtecan reported a median OS of 12.0 months in a phase 2 trial.
* Hansoh reported no grade 4 or 5 interstitial lung disease (ILD) events in the ris-rez trial.
* GSK started a global phase 3 ris-rez trial last year with data expected in 2027.
Executive Summary
GSK and Hansoh Pharma are developing risvutatug rezetecan (ris-rez), a B7-H3-directed antibody-drug conjugate for relapsed small cell lung cancer (SCLC). In a phase 3 trial conducted in China, ris-rez demonstrated a median overall survival of 18.5 months, compared to 10.3 months for patients receiving topotecan. This performance exceeds the reported median overall survival of competitors, including Amgen’s Imdelltra (13.6 months) and Merck and Daiichi Sankyo’s ifinatamab deruxtecan (12.0 months).
Significant uncertainty remains regarding whether these results will translate to global populations, as the pivotal trial was limited to Chinese sites. GSK is currently conducting a global phase 3 trial with results expected in 2027. Additionally, while ris-rez shows a similar rate of grade 3 interstitial lung disease (ILD) to its competitors, the absence of fatal ILD events in the Hansoh trial may provide a safety advantage. Despite these results, some analysts remain skeptical about the asset's differentiation and projected sales.
Full Take
The strongest version of this narrative is that GSK has identified a potent new ADC for SCLC that outperforms existing second-line standards in survival and potentially offers a superior safety profile regarding fatal lung toxicity. The data suggests a significant leap in efficacy that could redefine the treatment landscape if replicated globally.
The primary tension here is the "geographic translation gap." The narrative relies heavily on the assumption that clinical outcomes in China are proxy for global outcomes. To bridge this, GSK utilizes a secondary asset (mocertatug rezetecan) as an evidentiary bridge, suggesting that because one drug translated well, another will too. This is a logical leap, not a clinical certainty. Furthermore, the comparison between ris-rez and its rivals is an "apples-to-oranges" scenario; comparing a phase 3 trial to a phase 2 trial or different trial designs introduces variables that cannot be smoothed over by median OS numbers alone.
This reflects a broader paradigm in oncology: the rush to utilize "fast-follower" data from China to accelerate Western pipelines. While this increases the speed of innovation, it shifts the risk onto the global patient population who must wait for the 2027 data to confirm if the "Chinese edge" is a biological reality or a trial artifact.
Patterns detected: none
Bridge Questions:
1. If the 2027 global data shows a significant drop in median OS compared to the Chinese trial, what specific variables (genetics, standard of care, trial design) would likely be the cause?
2. Does the absence of fatal ILD events in a single trial provide enough statistical power to claim a safety "edge" over competitors?
Counterstrike Scan: A coordinated campaign to inflate GSK's stock price would lean heavily on the 18.5-month figure while burying the 2027 timeline and the geographic limitations. The actual content avoids this by explicitly mentioning analyst skepticism and the lack of global data. Clean.
Sentinel — Human
The text is a well-structured synthesis of clinical trial results and subsequent commentary regarding data comparability across different global development pathways, indicating human journalistic analysis.